Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198455 | 0.94 | EPHX1 (0.45) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2198239 | 0.93 | — | — | |
| SCHEMBL7786789 | 0.92 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL5361321 | 0.92 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL20597382 | 0.92 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL15104972 | 0.89 | — | — | |
| SCHEMBL2197798 | 0.87 | EPHX1 (0.42) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL3684347 | 0.86 | EPHX1 (0.60) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL13294283 | 0.86 | EPHX1 (0.60) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL30688061 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2125792-B1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2125792-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
| US-4581372-A | ANTIBODY STIMULANTS;IMMUNOLOGY | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1986-04-08 | — | — | US | disclosed |
| US-4340543-A | ANTICANCER AGENTS, ANTITUMOR AGENTS, IMMUNOSTIMULANTS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1982-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | EPHX1 372/4885LMNA 4732/4885POLB 2926/4885 |
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | EPHX1 372/4885LMNA 4732/4885POLB 2926/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | EPHX1 75/4885LMNA 2432/4885POLB 416/4885 |
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | EPHX1 372/4885LMNA 4732/4885POLB 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.